GlassScriptPhysician profile
Edward D Contreras
NPI 1609826445
$2,485.30
in general payments reported to CMS, 2019-2025
27 companies · $395 in 2025
The $395 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $246 · 2020: $136 · 2021: $135 · 2022: $415 · 2023: $429 · 2024: $730 · 2025: $395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,539 · Education: $14.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,539.37 |
| Education | $14.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $398.19 | 2019-2025 | Viberzi, Linzess |
| Phathom Pharmaceuticals, INC. | $324.90 | 2024-2025 | Voquezna |
| Celgene Corporation | $269.16 | 2022-2024 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $228.52 | 2022-2023 | Zeposia |
| Genzyme Corporation | $215.20 | 2024-2025 | |
| Axonics, INC. | $142.20 | 2024 | Axonics |
| Abiomed | $125.90 | 2025 | |
| Shionogi INC | $96.50 | 2020 | |
| Merck Sharp & Dohme LLC | $87.34 | 2021-2023 | Dificid |
| Allergan, INC. | $78.79 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.70 | 2019 | |
| Janssen Biotech, INC. | $49.08 | 2021-2025 | Tremfya |
| Lilly USA, LLC | $47.91 | 2024 | Omvoh |
| Redhill Biopharma INC. | $41.14 | 2021 | |
| Astellas Pharma US INC | $40.07 | 2023-2024 | Vyloy |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $34.47 | 2019 | |
| Ferring Pharmaceuticals INC. | $33.76 | 2023 | Rebyota |
| Amgen INC. | $29.18 | 2021-2025 | Uplizna |
| Medtronic, INC. | $27.37 | 2023-2024 | Interstim, Gi Genius |
| Gilead Sciences, INC. | $22.67 | 2019 | |
| Endogastric Solutions, INC | $20.88 | 2019 | |
| Ardelyx, INC. | $20.08 | 2025 | Ibsrela |
| Daiichi Sankyo INC. | $19.00 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $18.95 | 2024 | Iqirvo |
| Enterra Medical, INC. | $15.49 | 2024 | |
| Ucb, INC. | $13.71 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Contreras listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.